Brad L. Tade Sells 15,000 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA) Stock

ADMA Biologics, Inc. (NASDAQ:ADMA) CFO Brad L. Tade sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total value of $317,250.00. Following the completion of the transaction, the chief financial officer now owns 199,433 shares of the company’s stock, valued at $4,218,007.95. The trade was a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

ADMA Biologics Trading Down 0.6 %

Shares of ADMA opened at $21.18 on Monday. The stock has a market capitalization of $5.01 billion, a PE ratio of 75.64 and a beta of 0.64. The company’s fifty day moving average is $18.86 and its 200 day moving average is $14.89. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. ADMA Biologics, Inc. has a fifty-two week low of $3.60 and a fifty-two week high of $23.64.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The firm had revenue of $119.84 million for the quarter, compared to the consensus estimate of $107.25 million. During the same period in the previous year, the firm posted $0.01 EPS. Sell-side analysts expect that ADMA Biologics, Inc. will post 0.52 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ADMA Biologics

Several institutional investors have recently modified their holdings of the stock. Sei Investments Co. raised its holdings in ADMA Biologics by 176.0% during the 1st quarter. Sei Investments Co. now owns 393,481 shares of the biotechnology company’s stock valued at $2,597,000 after buying an additional 250,925 shares during the period. ProShare Advisors LLC raised its stake in shares of ADMA Biologics by 9.2% in the first quarter. ProShare Advisors LLC now owns 54,293 shares of the biotechnology company’s stock valued at $358,000 after acquiring an additional 4,570 shares during the period. CANADA LIFE ASSURANCE Co lifted its holdings in shares of ADMA Biologics by 114.3% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 54,049 shares of the biotechnology company’s stock worth $357,000 after acquiring an additional 28,832 shares during the last quarter. Shell Asset Management Co. purchased a new position in shares of ADMA Biologics during the 1st quarter worth about $155,000. Finally, EntryPoint Capital LLC bought a new position in ADMA Biologics during the 1st quarter valued at about $31,000. 75.68% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $20.00 target price on shares of ADMA Biologics in a research report on Friday, September 20th. HC Wainwright increased their price objective on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a report on Friday, November 8th. Finally, Raymond James lifted their target price on ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a report on Friday, November 8th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.